HBsAg REDUCTION BY NASAL ADMINISTRATION OF A THERAPEUTIC VACCINE CONTAINING HBsAg AND HBCAG (NASVAC) IN PATIENTS WITH CHRONIC HBV INFECTION: THE RESULTS OF 18 MONTHS FOLLOW UP